| abstract |
The present invention relates to macrocyclic compounds of formula (I), where: A is -S-, -S (= O) -, among others; L is optionally substituted C2-C6-alkylene; X and Y are CH or N where if one is CH and the other is N; R1 is optionally substituted C1-C6-alkyl, C3-C6-alkenyl, among others; R2, R3 and R4 are H, F, among others. Preferred compounds are: (rac) -16,20-Difluoro-9 - [(S-methylsulfonimidoyl) methyl] -2,3,4,5-tetrahydro-12H-13,17- (azeno) -11, 7- ( methene) -1,6,12,14-benzodioxadiazacyclononadecin; 15,19-Difluoro-8 - [(methylsulfanyl) methyl] -3,4-dihydro-2H, 11H-12,16- (azeno) -10,6- (methene) -1,5,11,13-benzodioxadiazacyclooctadecin , among others. Also refers to a combination, pharmaceutical composition, drug, and process. Said compounds inhibit the cyclin-dependent kinase 9 (CDK9) enzyme, being useful in the treatment and / or prophylaxis of hyperproliferative disorders, infectious diseases induced by viruses, among others. |